DCVC
DCVC, established in 2010 and based in Palo Alto, California, is a venture capital firm focusing on early-stage investments in deep tech companies. The firm backs entrepreneurs leveraging advanced technologies to drive transformative change across various sectors, including artificial intelligence, manufacturing, and life sciences. DCVC's portfolio comprises companies that combine cutting-edge science and technology with unique computing and algorithmic advantages, aiming to reduce capital and operational expenses. DCVC Bio, a subsidiary founded in 2018 and based in San Francisco, specializes in investing in early-stage life science companies powered by deep tech approaches, targeting sectors such as therapeutics platforms, agriculture, and industrial biotechnologies. Both DCVC and DCVC Bio are registered investment advisers.
Past deals in Newfoundland
Sequence Bio
Seed Round in 2016
Sequence Bio is a biotechnology company focused on advancing drug discovery and development through genome therapy. Leveraging the unique genetic characteristics of isolated populations, particularly those in Newfoundland, the company collects DNA and health information to enhance the identification of drug targets. This approach aims to improve the treatment of complex and inherited diseases, ultimately addressing the high failure rate of drug candidates and expediting access to effective therapies for patients in need. By utilizing genetic insights, Sequence Bio seeks to transform the landscape of medicine and deliver better health outcomes.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.